Correlation Between Adicet Bio and Acrivon Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Adicet Bio and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Adicet Bio and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Adicet Bio and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on Adicet Bio and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Adicet Bio with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Adicet Bio and Acrivon Therapeutics,.

Diversification Opportunities for Adicet Bio and Acrivon Therapeutics,

0.47
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Adicet and Acrivon is 0.47. Overlapping area represents the amount of risk that can be diversified away by holding Adicet Bio and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and Adicet Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Adicet Bio are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of Adicet Bio i.e., Adicet Bio and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between Adicet Bio and Acrivon Therapeutics,

Given the investment horizon of 90 days Adicet Bio is expected to under-perform the Acrivon Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Adicet Bio is 1.23 times less risky than Acrivon Therapeutics,. The stock trades about -0.2 of its potential returns per unit of risk. The Acrivon Therapeutics, Common is currently generating about -0.07 of returns per unit of risk over similar time horizon. If you would invest  927.00  in Acrivon Therapeutics, Common on August 28, 2024 and sell it today you would lose (211.00) from holding Acrivon Therapeutics, Common or give up 22.76% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Adicet Bio  vs.  Acrivon Therapeutics, Common

 Performance 
       Timeline  
Adicet Bio 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Adicet Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Acrivon Therapeutics, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Adicet Bio and Acrivon Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Adicet Bio and Acrivon Therapeutics,

The main advantage of trading using opposite Adicet Bio and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Adicet Bio position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.
The idea behind Adicet Bio and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Complementary Tools

AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stocks Directory
Find actively traded stocks across global markets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities